Production of Recombinant Biopharmaceuticals in <i>Chlamydomonas reinhardtii</i>

This review aimed to present <i>Chlamydomonas reinhardtii</i> as an alternative for heterologous protein production, especially for biopharmaceuticals, and its general characteristics when compared with other expression systems. The need to produce heterologous proteins for industrial in...

Full description

Bibliographic Details
Main Authors: Cesar Andres Diaz Arias, Caroline Frere Martiniuc de Oliveira, João Vitor Dutra Molino, Livia Seno Ferreira-Camargo, Marcelo Chuei Matsudo, João Carlos Monteiro de Carvalho
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Plant Biology
Subjects:
Online Access:https://www.mdpi.com/2037-0164/14/1/4
Description
Summary:This review aimed to present <i>Chlamydomonas reinhardtii</i> as an alternative for heterologous protein production, especially for biopharmaceuticals, and its general characteristics when compared with other expression systems. The need to produce heterologous proteins for industrial interest, therapeutic ends, and diagnostic kits has led to the development of recombinant microalgal technology. This technology presents some interesting features, such as rapid growth and low transgene dispersion compared to plants, the ability to fold complex proteins compared to bacteria, and low production costs compared to other expression systems, such as yeast and mammalian cells. Overall, <i>C. reinhardtii</i> heterologous protein expression is coming of age with several research groups focused on developing an optimal producer strain.
ISSN:2037-0164